8:45 am Chair’s Opening Remarks

Uncovering the Latest Technology for Advancing the Peptide Therapeutics Field

9:00 am Peptide Drug Hunting: Entrepreneurial Science & Technologies Empowering Breakthrough Medicines

  • Tomi Sawyer Chief Drug Hunter & President, Maestro Therapeutics


• High level overview of peptide drug discovery and current lead identification strategies

• Peptide lead optimization integrating structural biology and computational chemistry

• Examples of peptide drug development with potential to be breakthrough medicines

• Creation of a worldwide entrepreneurial consortium for peptide drug hunting

9:30 am Exploring Advances in Screening Platforms to Propel Forward Discovery


• Delving into the science and success behind the PeptiDream platform

• Optimization process for orally available macrocyclic peptides

• Future development of peptide-drug conjugates and multi-functional peptide conjugates

10:00 am Morning Break & Networking

11:00 am Developing Oral Peptide Therapeutics at the Speed of Light

  • Pete Gough chief scientific officer, Nimble Therapeutics


• Describing our platform technology and how it enables custom synthesis of greater than 100 million peptides overnight

• Examples of how we have used our platform to optimize properties of peptide therapeutics

• Highlights of our internal oral peptide therapeutics discovery programs

11:30 am Exploring Vivtex’s Robotic Screening Platform for Optimizing the Delivery of Oral Peptides


• Background behind Vivtex’s approach to developing orally administered peptides with high GI absorption

• Understanding the scientific rationale underlying Vivtex’s GI Tract-Tissue Robotic Interface System (GI-TRIS)

• Case studies detailing the use of this screening system to facilitate oral peptide delivery

12:00 pm Lunch & Networking

Advances in Applications for Peptide-Based Therapeutics – Exploring Their Untapped Potential

1:00 pm Novel BBB-Surpassing Peptide Structure for Unlocking New Treatment Avenues

  • Andy Slee Chief Scientific Officer, Protagenic Therapeutics


Developing peptide-based drugs for the treatment of affective disorders

• Peptides derived from natural genomic sequences with low toxicity and the ability to surpass the blood-brain-barrier

• Exploring PTIs lead compound, PT00114, which is currently in clinical trials

1:30 pm Uncovering the Discovery of FOG-001, a First-And-Only-In-Class Direct Β-Catenin Inhibiting Peptide

  • Jonathan Hurov Executive Vice President - Discovery Biology, Fog Pharma

2:00 pm Afternoon Break & Networking

Exploring the Recent Clinical Successes Within Peptide Based Therapeutics to Drive Forward Future Success on Novel Targets

3:00 pm Discovery of Zilucoplan: A Peptide Complement C5 Inhibitor in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis


• Brief introduction of UCB and origin of zilucoplan

• Examining the biology background and early discovery of zilucoplan – a small, subcutaneously administered, macrocyclic peptide

• Discussing lessons learnt from this clinical success and future directions

3:30 pm Protagonist Therapeutics Peptide Platform: The Journey from De Novo Discovery to Phase 3 Clinical Development Programs

  • Ashok Bhandari Chief Drug Discovery & Preclinical Development Officer, Protagonist Therapeutics


• De novo peptide discovery methods highlighting our clinical programs, in particular the J&J collaboration on JNJ-2113

• Peptide optimization strategies

• Lessons learned to be applied to future targets

4:00 pm Chair’s Closing Remarks

4:05 pm Scientific Poster Presentation


This is an informal session to help you connect with your peers in a relaxed atmosphere and forge new and beneficial relationships. With an audience of peptide experts eager to hear the latest innovations and positive movement, you will have the opportunity to display a poster presenting your own work. Additionally, you will have the chance to review others’ posters displaying cutting-edge work from drug discovery right through to exciting clinical trial updates.